AMRX PDUFA decision: a positive outcome, +5.3%

On January 31, 2023, Amneal Pharmaceuticals, Inc. reached its PDUFA decision. The result was a positive outcome, and the stock moved +5.3% in the window around the event. It had already run +7.5% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.